Back to search

Peptide record

TPDB40953

C16-E4Y Anticancer standard
5 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB40953
C16-E4Y
Anticancer
Cancer-related peptides
CancerPPD 2.0
standard
No
A 5-aa standard natural anticancer peptide sequence curated from CancerPPD 2.0, with an available 3D structural model.
N-terminal: Palmitoyl
Sequence
EEEEY
Physicochemical Analysis
C29H39N5O15
ARNDCQGHILKMFPSTWV
E
697.65
2.96
0
4
1
-4
7.14
-3.060
0.00
Mammalian: 1 hour Yeast: 30 min E.coli: >10 hour
1490
213.57
1
Residue Composition
number
0
A
0
R
0
N
0
D
0
C
4
E
0
Q
0
G
0
H
0
I
0
L
0
K
0
M
0
F
0
P
0
S
0
T
0
W
1
Y
0
V
Amino Acid Distribution
A: 0 R: 0 N: 0 D: 0 C: 0 E: 4 Q: 0 G: 0 H: 0 I: 0 L: 0 K: 0 M: 0 F: 0 P: 0 S: 0 T: 0 W: 0 Y: 1 V: 0
Chemical Descriptors
5
C29H39N5O15
697.65
2.96
-4
7.14
-3.060
Free
L
Linear
Palmitoyl
Anticancer
Synthetic
Evidence Records 4 records
Evidence 1 Activity

Activity

10 % cell viability at 0.05 wt %
Anticancer

Target

Skin Cancer
A-431
Skin

Assay & Model

WST-8 assay
24-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2022

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

60% cell viability at 0.05 wt %
Anticancer

Target

Cervical Cancer
HeLa
Cervix

Assay & Model

WST-8 assay
24-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2022
Evidence 3 Activity

Activity

50 % cell viability at 0.05 wt %
Anticancer

Target

Liver Cancer
HepG-2
Liver

Assay & Model

WST-8 assay
24-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2022
Evidence 4 Activity

Activity

50 % cell viability at 0.05 wt %
Anticancer

Target

Breast Cancer
MCF-7
Breast

Assay & Model

WST-8 assay
24-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2022